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ROLE OF ANTI-HYPERTENSION CLASS DRUGS IN THE 
PATHOGENESIS OF DIABETES MELLITUS COMPLICATIONS 
JAMES D. MACKENZIE 
ABSTRACT 
 The diabetic patient is subject to many complications in the event of poor 
control of blood glucose or blood pressure. Diabetic nephropathy is the leading 
cause of kidney dialysis in the developed world. Diabetic retinopathy is one of the 
leading causes of blindness in the United States. Cardiovascular diseases are the 
leading cause of morbidity in the United States. There are many different factors 
that predispose people to developing these conditions. Among these factors in a 
diabetic patient, hypertension has been shown to be strongly correlated with 
progression of micro and macrovascular complications. There are several 
antihypertensive treatment options for lowering blood pressure including 
angiotensin receptor blockers, angiotensin converting enzyme inhibitors, calcium 
channel blockers, beta adrenergic receptor blockers, and diuretics among others. 
By lowering blood pressure in diabetic patients comorbid with hypertension, 
complications arising from either condition have been shown to be reduced to a 
greater extent than can be explained with either normal blood pressure or blood 
glucose levels. However, there is mounting evidence that certain beta-adrenergic 
receptor blockers cause insulin desensitization, adverse lipid metabolism, and 
poor carbohydrate metabolism. Furthermore, hypertension is a complex disease 
process especially when considered from the perspective of the patient with 
  vii 
diabetes. There are many possible underlying mechanisms for the hypertension 
and resulting complications, so it may be important for the prescribing physician 
to employ a combination of different classes of antihypertensive pharmaceuticals 
when treating their patients. Although some antihypertensive agents may cause 
some adverse effects in patients, they are usually very well tolerated, and 
attempts should be made to incorporate them into a treatment plan for 
preventing the onset of diabetic complications. 
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INTRODUCTION 
In the United States, it is estimated that over 9% of the population has 
been diagnosed with some form of diabetes- over 30 million people1. Of those 30 
plus million people, 7.2 million were not aware of living with, or did not report 
having, a definitive diagnosis of diabetes1. Yet, diabetes does not affect all 
populations homogenously; some groups are more likely to have diabetes than 
others, which leads to disparities in health outcomes between groups.  
 
Among the population of older individuals in the United State, prevalence 
of diabetes reaches a staggering 25.2% of Americans1. Native Americans and 
Alaska Natives have the highest prevalence of diabetes at all age groups, with an 
estimated prevalence of 14.9% among men, and 15.3% among women. At the 
same time, Chinese-Americans had the lowest prevalence of diabetes among all 
age groups, at 4.3% of their population in the United States1. Additionally, 
diabetes is more prevalent in those of lower educational status, a proxy for 
socioeconomic status, at 12.6% prevalence in people with less than a high school 
education versus 7.2% among those with higher than high school education1. 
Strikingly, many people in the United States are on the cusp of diabetes without 
even realizing it. Based on fasting blood glucose levels, an estimated 33.9% of 
U.S. adults have qualified for prediabetes (based on a fasting blood glucose 
between 100 and 125 mg/dL) in 2015, while nearly half, 48.3%, of adults over 65 
qualified for pre-diabetes1. Treatment modalities of diabetes often range in price 
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from inexpensive, to the latest expensive technology for treating the disease. 
Multiply the individual costs of treatment of diabetes by 30 million people, and 
the financial burden on the American people becomes enormous, both in terms of 
direct medical care and lost productivity. In 2012, the estimated cost of diabetes 
was 245 billion dollars, a 41% increase from 2007; more than 1 in 5 healthcare 
dollars are spent on the care for people diagnosed with diabetes5. Table 1 shows 
the prevalence of several common complications among diabetic patients.  
 
Table 2. Prevalence of complications among adults aged greater than 
or equal to 18 years with diagnosed diabetes for selected causes, 
United States, 20141 
 
 
Diabetes Mellitus is characterized by chronic hyperglycemia due to either 
an insufficiency of total insulin secretion or lack of response to insulin on 
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effectors. There are two primary types of diabetes Mellitus, defined by an 
individual’s endogenous insulin production3: type 1 diabetes mellitus (insulin-
dependent diabetes) and type 2 diabetes mellitus (insulin-independent diabetes 
mellitus)6. Of the two main types, type 2 is by far the more common, accounting 
for 90-95% of the proportion of diabetes. Furthermore, the world population 
diagnosed with diabetes is expected to reach numbers in excess of 430 million by 
20307. While the human body relies on glucose to fuel its metabolic processes, 
glucose is a highly reactive molecule because it contains six highly reactive 
hydroxyl groups. These hydroxyl groups have a propensity to nucleophilically 
bind the reactive groups on proteins, nucleic acids, and lipids through non-
enzymatic reactions to form covalent bonds. These reactions are collectively 
known as glycation, and must be distinguished from glycosylation (which is an 
enzymatic reaction), to form advanced glycation end products (AGEs)8. These 
advanced glycation end products are implicated in causing many diabetic 
complications through interactions with protein kinase C, increased oxidative 
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stress, reactive toxic metabolites, and altering gene expression. Figure 1 
summarizes these effects and pathways. 
 
Figure 1 Proposed mechanisms by which hyperglycemia induces 
vascular complications.9 
Another example of glycation is glycated hemoglobin, in which the free 
aldehyde group of glucose forms a covalent bond with the unprotonated form of 
free amino groups on hemoglobin10. The measure of the percentage of glycated 
hemoglobin in the body is the A1C, and for people without diabetes, the normal 
glycated hemoglobin ranges from 4-6% of the red blood cells in the body11. The 
A1c results give a measure of average blood glucose over the past 2-3 months, 
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with high values corresponding to high average blood glucose levels, and low 
values corresponding to low average blood glucose levels11. Naturally, the A1C test 
is a valuable tool for assessing whether a patient is at risk of developing diabetes, 
with higher values (and by extension, average glucose values) correlated with 
greater likelihood of developing complications11. This is important to note 
because carbohydrates comprise about fifty percent of the typical American diet. 
Additionally, the carbohydrates favored by Americans tend to rate higher on the 
glycemic index12. 
 
Among the many complications of diabetes, retinopathy is one of the most 
devastating. The estimated overall prevalence of diabetic retinopathy is 40.3% of 
those with diabetes mellitus, with 8.2% having vision-threatening diabetic 
retinopathy, with type 1 diabetic patients more likely than those with type 2 
diabetes to develop retinopathy13. Additionally,  differences in the prevalence of 
diabetic retinopathy were found between racial groups in the United States. 
Hispanics had the highest rate of diabetic retinopathy, followed by African 
Americans, with White Americans having the lowest rate of diabetic 
retinopathy13. Current treatment for diabetic retinopathy is centered on surgical 
intervention and alleviation of intra-orbital pressure, along with preventative 
measures.  
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Another complication of diabetes is nephropathy, in which the nephron of 
is compromised by podocyte detachment and reduced endothelial cell 
fenestration14. Diabetic nephropathy often leads to kidney disease and end-stage 
renal failure, and is present in twenty to forty percent of diabetic patients15. 
Worsening of diabetic nephropathy leads to greater risk of hypertension, which 
inherently causes a feedback loop of nephron damage.  
Lastly among the major microvascular complications associated with 
diabetes is neuropathy. Peripheral neuropathy is the most common of diabetic 
complications and involves somatic, motor, and autonomic nerves damage 
resulting in pain or numbness16. Neuropathy develops as a consequence of the 
formation of advanced glycated end products, excessive release of cytokines, 
oxidative stress, as well as other factors 16. Neuropathy can lead to a loss of 
feeling in the lower limb, which is predictive of a need for amputation, carrying 
immense costs and personal strain17. Currently, there are no treatments for 
neuropathy, with clinical considerations made mostly towards tight blood glucose 
control in order to prevent the worsening of conditions.  
The body harnesses a tightly-controlled system of hormones to regulate 
the delicate balance between glucose uptake by cells, glucose creation 
(gluconeogenesis, glycogenolysis), and hunger for carbohydrate-rich foods to 
maintain optimal bloodstream glucose concentration. Excess amount of glucose 
in the blood dramatically increases the risk of complications through AGEs18. The 
hormone responsible for the uptake of glucose by cells is insulin, and it exerts its 
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effects through a tyrosine kinase insulin receptor, which through a series of 
phosphorylations of effector molecules causes the translocation of the glucose 
transporter, GLUT4, to the cell surface of muscle and adipose cells 18. Figure 2 
depicts the cascade of effects leading to GLUT4 plasma membrane insertion. 
Insulin also signals to the liver to produce glycogen while simultaneously 
inhibiting hepatic glucose production18. Under normal conditions, glucose is the 
sole source of energy for the brain. However, often overlooked is the 
interconnectedness between diabetes and hypertension. Peripheral vascular 
resistance combined with heart rate are the considerations for blood pressure. In 
fact, postprandial glucose spikes in blood glucose are associated with a thickening 
of arteries. A team in Italy found that, among 644 people recruited to the study 
with type 2 diabetes, carotid artery intima-media thickness increased over a 4 
year period19. 
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Figure 2. Cellular signalling cascade of insulin causes translocation of 
GLUT4 to the cell surface. (Saini, 2010.) 
Hypertension has been previously defined in 2004 by the National High 
Blood Pressure Education Program in the seventh report of the Joint National 
Committee to be either systolic blood pressure over 140 mmHg or diastolic blood 
pressure above 80 mmHg. Normal blood pressure was defined as a systolic blood 
pressure under 120 mmHg and diastolic blood pressure below 80 mmHg, with 
the existence of a prehypertensive state in between the hypertensive and normal 
values20. Since then, the United States has adopted new classifications of 
hypertension, with stage 1 at a threshold of 130-139 mmHg and stage 2 (more 
severe) beginning over 140 mmHg systolic blood pressure21. Table 2 shows the 
guidelines for defining blood pressure.  
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Table 3. New guidelines for the diagnosis of hypertension in the 
United States as of 2017 with respect to systolic blood pressure 
(SBP) and diastolic blood pressure (DBP). (Whelton PK, et al. 
2017) High Blood Pressure Clinical Practice Guideline 
 
There are numerous complications attributed to hypertension, among 
which are neuropathy, retinopathy, cardiovascular disease, and kidney disease. 
This poses another problem for hypertension because of a cycle in hypertension. 
When kidneys start to fail, the glomerular filtration rate goes down, which causes 
salt and water retention, subsequently increasing the plasma volume. This in 
itself causes a release of renin in response to the decreased glomerular filtration 
rate, increasing the Angiotensin II. Angiotensin II then upregulates aldosterone 
and sympathetic excitation and feeds back into increasing blood pressure. 
The standard of care for treating hypertension in patients with diabetes is 
to keep blood pressure below 130 mmHg systolic pressure22. Furthermore, 
patients with hypertension are 2.5 times more likely to develop type 2 diabetes 
several years down the line as compared to people with normal blood pressure, as 
seen in a study with 12,500 people23. This suggests that these conditions 
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commonly coexist in people. Moreover, each disease serves to exacerbate the 
conditions caused by the other 23. 
 
 
Also of interest is the observation that diabetes mellitus is in itself a 
significant predictor of incident hypertension, and hypertension is at baseline a 
predictor of diabetes mellitus24. Indeed, there is evidence to suggest that 
hypertensive individuals are more likely to show disturbances in carbohydrate 
metabolism, a hallmark of diabetes25. Furthermore, lowering blood pressure has 
been shown to decrease the incidence of cardiovascular and microvascular 
damage26. It has also been shown that a large proportion of diabetics display poor 
ability to control their hypertension24. Up to 75% of adults with diabetes also 
have hypertension, and those with hypertension often show signs of diabetes2. In 
2008 an Italian team found that over a course of five years carotid artery 
thickening correlates directly with postprandial blood glucose increases in 
diabetic patients measuring their blood glucose at home19. Most patients with 
type 2 diabetes will either develop or die of macrovascular complications; it is far 
more common than microvascular complications7. This  body of evidence 
illustrates the interconnectedness of the two disease processes, highlighting the 
public health crises arising from the positive feedback loop of the two diseases. 
While Renin-Angiotensin System inhibitors are first-line antihypertensive 
therapy for those with diabetes, there exists evidence that using several 
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medications in conjunction improves outcomes27, which could potentially lead to 
better patient outcomes and reduced financial cost of the diabetes burden. Table 
3 outlines therapeutic goals in treating several different complications associated 
with diabetes.  
Table 4 Screening performed for detection of microvascular 
complications in patients with type 2 diabetes. (Long and Dagogo-
Jack et al. 20112.) 
 
Complication Method Frequency Optimal Goals
Urine Microalbumin Annually* Albumin <30mg/24hr 
or Albumin- 
Creatinine 
ratio<30mg/g in 
random urine 
specimen
GFR estimation by 
serum creatinine
Annually GFR > 90 
mL/min/1.72m2
Initially
 Type 1: 3–5 years 
after onset
 Type 2: From 
diagnosis
Annually; more 
frequently if pregnant 
or progressive 
retinopathy
Daily self-inspection of 
feet
Every visit Intact skin
Comprehensive foot 
examination
Annually Normal examination
Examination for distal 
symmetric 
polyneuropathy
At diagnosis and 
annually
Early detection and 
limb preservation
Type 1: 5 years after 
diagnosis
Type 2: from 
diagnosis
Nephropathy
Retinopathy Dilated and 
comprehensive eye 
exam
Primary prevention, 
delay of progression 
and prevention of 
blindness from 
retinopathy
Neuropathy
Assessment for 
autonomic neuropathy
Early detection, 
symptom control, 
recognition of 
associated 
cardiovascular risk
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Specific Aims 
A vast amount of published research exists that is focused on the efficacy of anti-
hypertensive pharmaceuticals in the prevention of diabetic complications, 
specifically cardiovascular disease. This volume of data inherently prevents this 
relatively short analysis from being entirely comprehensive. The aims of the 
following analysis are instead to characterize the risk of diabetes complications 
due to hypertension. This thesis will attempt to better elucidate the role of several 
different, commonly prescribed, anti-hypertensive class pharmaceuticals in 
ameliorating the pathogenesis of diabetes complications through a review of the 
literature. Added consideration will be given to the socioeconomic disparities in 
health outcomes and analysis of economic factors that may make treatment more 
difficult to pursue. The thesis will pose a conclusion pertaining to the validity of 
various anti-hypertensive drugs in patients comorbid for hypertension and 
diabetes. The goal for someone reading this review is to gain a greater 
understanding of the complex processes that contribute to diabetic 
complications, as well as the need for flexible treatment options as it relates to 
treating these interconnected diseases.  
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Current treatment outcomes for blood pressure in patients with 
diabetes and hypertension 
 
 There are currently many options for the treatment of hypertension, 
including lifestyle changes. Chief among lifestyle modifications are several 
dietary approaches to decrease blood pressure. This dietary approach  
emphasizes eating fruits and vegetables, low-fat dairy products, and reducing 
sodium intake, while simultaneously reducing the amount of red meat, sugar, 
total fat, and cholesterol intake28. Barring lifestyle modifications, there are many 
popular pharmaceutical options that target various mechanisms for the 
amelioration of hypertension into a more satisfactory range for the patient with 
diabetes. There are many popular options, but the following medications shown 
in Table 4 are commonly used29. 
Table 5 Average reduction in systolic blood pressure from several 
popular antihypertensive class drugs over the course of 24 hours 
(mmHg).30 
 
These antihypertensive drugs all have unique sites of action and mechanisms 
designed to lower blood pressure. The general targets of these pharmaceuticals 
are outlined in general terms on figure 3.  
Half standard dose Standard Dose
ACE inhibitors 6.9 8.5
Angiotensin receptor blockers 7.3 10.3
Beta blockers 7.4 9.2
Calcium antagonists 7.4 8.8
Thiazides 7.4 8.8
 14 
 
Figure 3: Cycle of hypertension and sites of action of various 
antihypertensive drugs. Hypertension causes nephrosclerosis (and 
subsequently afferent arteriole constriction), in which kidneys 
become ischemic, stimulating renin release, which upregulates 
angiotensin II, leading to higher blood pressure through a variety of 
pathways.4 
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ACE inhibitors inhibit the formation of Angiotensin 2, which causes upregulation 
of Aldosterone and generalized vasoconstriction through the action of 
sympathetic excitation. Calcium channel blockers cause vascular smooth muscle 
relaxation which in turn decreases peripheral vascular resistance. Angiotensin 2 
receptor blockers inhibit binding of angiotensin 2 to their associated receptor on 
blood vessel walls, which leads to vasodilation. Beta blockers generally block the 
beta-adrenergic receptor from binding their agonist, as well as blocking renin 
release and decreasing heart rate which decreases blood pressure. Then there are 
thiazide diuretics, which are the most commonly prescribed diuretics31. Thiazide 
diuretics exert their blood pressure lowering effects by blocking the reabsorption 
of sodium in the distal convoluted tubule, creating a sodium gradient from the 
blood to the nephron. This gradient then pulls water into the tubules, which 
lowers the plasma volume, lowering blood pressure3.  
 The importance of treatment of hypertension is paramount. In a European 
trial Systolic Hypertension in the Elderly Program study, 583 elderly patients 
with diabetes and hypertension were enrolled in a study comparing control of 
blood pressure vs placebo and normal care. The intensive group experienced a 
drop in blood pressure of 9.8 mmHg systolic and 2.2 mmHg drop in diastolic 
blood pressure. These changes resulted in a significant decrease in total 
cardiovascular events and a decrease in all-case mortality32. 
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 Additionally, there are several varying guidelines in the treatment and 
prevention of complications in patients with diabetes comorbid with 
hypertension. Although it is useful to employ both glycemic and blood pressure 
control, there is evidence to suggest that the benefits of tight blood pressure 
control outweigh the benefits of good blood glucose control in curbing 
complications in those patients with diabetes and hypertension33. In the United 
Kingdom Prospective Diabetes Study of hypertension, 1148 patients with newly 
diagnosed diabetes were randomly grouped into tight or less-tight control of 
blood pressure (180/105 vs 150/85 mmHg), as well as tight vs less-tight control 
of their blood glucose levels (mean hemoglobin A1c levels 7.9% vs 7%). Clinical 
outcomes were measured in terms of fatal and non-fatal, as well as deaths related 
to diabetes and general causes of mortality. Microvascular disease was assessed 
through measures of urinary albumin excretion and retinal assessment for 
proliferation of blood vessels. Those in the tight control of blood pressure group 
experienced a 24% decrease in diabetes-related end-points, and 32% decrease in 
diabetes related deaths, 44% reduction in strokes, and 37% reduced amount of 
microvascular complications33. These outcomes were stronger than those of the 
tight glycemic control group vs less tight glycemic control by factors of absolute 
risk reduction of 2-5 times greater. Even the number needed of patients needed 
to be treated (NNTb) is greater in the group of tight blood glucose control vs 
those with tight blood pressure.  The results are shown in table 5. 
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Table 6.Effectiveness of tight glycemic control vs tight blood pressure 
control in UK Prospective Diabetes Study34 
 
  Even tight control of blood pressure vs moderate control of hypertension 
(diastolic blood pressure goal of 75 mmHg vs 80-89 mmHg) achieved significant 
reduction in diabetic complications. The Appropriate Blood Pressure Control in 
Diabetes trial followed 470 patients with type 2 diabetes comorbid with 
hypertension separated into tight vs moderate control of their blood pressure 
over a period of 5.3 years. The group of patients undergoing intensive blood 
pressure control therapy demonstrated a decrease in all-cause mortality25. 
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Efficacy of ACE Inhibitors in the prevention of adverse cardiovascular 
outcomes in patients with hypertension and diabetes 
 
The Heart Outcomes and Prevention Evaluation study evaluated the 
effects of ACE inhibitor (ramipril) on cardiovascular outcomes, microvascular 
complications, and total mortality. In the study, 3577 patients with diabetes and 
at least one risk factor for cardiovascular complications were randomly assigned 
to either an ACE inhibitor (ramipril 10 mg/day) or a placebo. The study was 
actually concluded 6 months early because of the clear benefits of ACE inhibitors 
on cardiovascular outcomes35. ACE  inhibitors were found to reduce the risk of 
myocardial infarction by 22%, nephropathy by 24%, and cardiovascular death by 
37%. Furthermore, the decrease in risk of outcomes was greater than that 
attributable solely to a decrease in blood pressure, suggesting a synergistic effect 
in reducing risk for people with diabetes and hypertension. which suggests a 
protective effect of ACE inhibitors on vasculature and kidney function35.  
 ACE inhibitors also demonstrated a protective effect on renal function in 
normotensive patients comorbid with type 2 diabetes. In a subset of the above 
study, 156 patients with type 2 diabetes, normal blood pressure, and signs of 
microalbuminuria were randomly assigned to ACE inhibitors or placebo to 
evaluate the effects on renal function at the end of a six year period36. ACE 
inhibitor therapy decreased albumin excretion at two years which then gradually 
increased up until the six-year follow-up. However, the placebo group increased 
 19 
far more dramatically at six years after the beginning of the trial, from 108 mg 
per twenty four hours to 134.5 mg per twenty four hours36. Furthermore, use of 
CE inhibitor decreased creatinine clearance as compared to placebo group users. 
Finally, ACE inhibitor use resulted in absolute risk reduction of 12.5% as 
compared to placebo for the development of microalbuminuria36.  
 
 
Efficacy of Angiotensin Receptor Blockers in the prevention of 
adverse outcomes in patients with diabetes comorbid with 
hypertension 
 
 There have been several studies that have assessed the efficacy of 
angiotensin receptor blockers in the attenuation of adverse outcomes for patients 
with diabetes and high blood pressure. In a randomized, double-blind study of 
1533 patients with type 2 diabetes and hypertension, patients were placed into 
groups comparing treatment modalities. Patients were prescribed either an 
angiotensin receptor blocker (losartan, 50 to 100 mg once daily) or placebo, both 
of which were taken with conventional antihypertensive treatment, for a mean of 
3.4 years4. Patients were then assessed for primary outcomes whether 
angiotensin receptor blockers would increase the time it took patients to double 
serum creatinine concentration, onset of end-stage renal disease, or total death. 
Patients were also assessed of secondary outcomes morbidity and mortality from 
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cardiovascular diseases, presence of protein in urine, and the progression rate of 
nephropathy/kidney disease4. 
 The group with angiotensin receptor blockers, losartan, reached a 
doubling of serum creatinine concentration (indicating a reduction in GFR by 
half), end-stage renal disease, or death in 327 patients as compared to 359 in the 
placebo group. The composite primary outcome was a combination of myocardial 
infarction, stroke, or cardiovascular death. Treatment with a angiotensin receptor 
blocker reduced the risk of patients reaching the primary composite end-point by 
16%, remaining even despite adjusting for reductions in blood pressure4. 
Treatment with angiotensin receptor blockers also lowered the risk of doubling 
serum creatinine concentration by twenty five percent, reduced the risk of end-
stage kidney disease by 28%. However, there was no difference between groups 
in morbidity and mortality4. There was also a potential protective effect in 
patients taking an angiotensin receptor blocker through the reduction in level of 
urinary protein by thirty five percent, while the group with the placebo 
medication tended to slightly increase proteinuria4. Furthermore, angiotensin 
receptor blockers reduced the rate of decline of renal function by 18%, as well as a 
15.2% reduction in decline of glomerular filtration rate over the course of 4 
years4. These results are shown in figures 4 and 5. 
 In a separate trial for angiotensin receptor blockers, 590 diabetic patients 
with microalbuminuria were enrolled to study the effects of angiotensin receptor 
blocker in comparison to a placebo. Patients were followed for two years, and the 
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treatment was found to be protective of kidney function irrespective of blood 
pressure differences37.  
 
Figure 4. Measures of primary outcomes in patients receiving 
angiotensin receptor blockers vs placebo in primary outcomes4 
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Figure 5. Changes from baseline in the levels of protein in urine in 
placebo group vs those taking angiotensin receptor blocker4 
 
Efficacy of beta-blocker class antihypertensive pharmaceuticals in 
prevention of diabetic complications 
 Beta blockers have been extensively studied in the pathogenesis of diabetic 
patients comorbid with hypertension and remain a viable option for lowering 
blood pressure. However, there are valid concerns about the tendency for 
patients on beta blockers to experience cardiovascular abnormalities while on the 
medication if patients have diabetes38. In a study that enrolled 5024 diabetic 
patients comorbid with hypertension, patients were randomly assigned to either 
receive beta adrenergic blocker therapy in addition to their standard 
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hypertension pharmaceuticals or not. They were then assessed for several 
endpoints including the primary outcome of a first occurrence of a cardiovascular 
event (myocardial infarction, stroke, unstable angina, cardiovascular death), as 
well as assessed for secondary outcomes all-cause death, severe hypoglycemia, 
and cardiovascular death. Results of statistically significant outcomes are shown 
in table 6. 
Table 7. Statistically significant measures of primary and secondary 
outcomes (CHD/HF are cardiac heart disease and heart failure, 
respectively) in various patient populations either on beta blocker 
therapy or traditional therapy38 
 
 It is theorized that beta blockers are associated with increased risk of 
severe hypoglycemia because of underlying mechanisms to blunt sympathetic 
No beta blockers beta blockers
All patients
Cardiovascular events 2.70% 4%
Cardiovascular deaths 0.60% 0.90%
Standard therapy group
Cardiovascular events 2.70% 4.50%
Patients with CHD/HF
Cardiovascular events 4.40% 5.50%
Patients widhout CHD/HF
Cardiovascular events 2.10% 3.00%
Intensive therapy
Severe hypoglycemia 1.70% 2.30%
Event rate per year
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response to low blood glucose levels. With the blockage of beta adrenergic 
receptors, a person is less likely to feel their low blood glucose, which in many 
cases is the first sign of low blood glucose levels38. 
 
Comparison of antihypertensive class drugs in prevention of diabetic 
complications 
  With so many options for antihypertensive class pharmaceuticals on the 
market, it is necessary to ascertain what the optimal first treatment step should 
be. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack Trial, 33357 patients with hypertension were further subdivided into 
several groups and followed over the course of eight years to track primary 
outcomes. These outcomes included combined fatal coronary heart disease or 
nonfatal myocardial infarction. Patients were given either ACE inhibitors, 
calcium channel blockers, or beta blockers in combination with diuretics. There 
was no difference between groups for risk of cardiovascular events or total 
mortality, however those patients treated with ACE inhibitors had a lower risk of 
myocardial infarction than those treated with calcium-channel blockers39. The 
same trial then took a subgroup of 12063 patients with diabetes comorbid with 
hypertension and tracked primary outcomes with respect to ACE inhibitors, 
thiazide diuretics, and calcium channel blockers. There was no significant 
difference seen between the groups in primary outcomes in terms of nonfatal 
myocardial infarction or death from coronary heart disease.  
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 In a separate study carried out in Norway, a subgroup of 727 patients with 
type 2 diabetes and hypertension were assessed for differences in cardiovascular 
end points or mortality. Patients were given either a calcium channel blocker 
(diltiazem) or beta blockers and diuretics40. At the end of the trial, blood 
pressures were similarly reduced, and there were no differences in cardiovascular 
poor end point outcomes or total mortality40.  
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CONCLUSION 
Antihypertensive pharmaceuticals are valuable tools in preventing the 
onset of diabetic complications when used in combination with various other 
therapies4. Numerous studies have unanimously concluded that treatment of 
hypertension in patients with diabetes has yielded a clear and consistent effect. 
When blood pressure is controlled in patients with diabetes comorbid with 
hypertension, cardiovascular end points were dramatically reduced, along with 
microvascular and macrovascular complications 4,36,38. It is also clear that an 
aggressive approach should be taken when treating patients with diabetes and 
hypertension. In the Hypertension Optimal Treatment randomized trial, just a 
four point difference in diastolic blood pressure (85 vs 81 mmHg) resulted in a 
decrease in the risk for cardiovascular complications in patients26. Taking all of 
the data into consideration however, leaves a physician with many options for 
treatment of such a complex disease process. 
There are many classes of antihypertensive class drugs, each of which 
works through their own unique mechanism. A prescribing physician should 
consider prescribing a combination of pharmaceutical interventions with the goal 
of treating a disease process as complex as hypertension in a diabetic patient. 
Many studies have thus far established a variety of antihypertensive 
pharmaceuticals as viable options for treating high blood pressure and the 
resultant complications, both microvascular and macrovascular. It is clear from 
the earlier cited studies that ACE inhibitors and angiotensin receptor blockers are 
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two fairly effective pharmaceuticals for the prevention of not only poor 
macrovascular outcomes in the form of cardiovascular disease and mortality, but 
also in microvascular diseases in the form of nephropathy and retinopathy4,37. 
Ultimately though, diabetes is a complicated disease that begets complications 
the longer a patient has the disease. Hypertension further complicates the 
treatment and outcomes of the patient with diabetes, making the treatment very 
difficult.  
 Diabetes is a complicated disease process that imposes huge lifestyle and 
pharmaceutical daily burdens on people. Diabetes brings with it daily challenges 
and choices that may overwhelm a patient when prioritizing specific treatment 
options. When hypertension plays into the equation, naturally the physician 
prescriber will question what the best treatment option may be for preventing 
and avoiding complications further down the line for the patient.  
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